Fabrazyme's single Fabry indication puts it under the IRA's orphan-drug exclusion, insulating it from Medicare price negotiation and leaving no disclosed rebate figure for any Fabry therapy in the US market.
Agalsidase beta (Fabrazyme, Sanofi Genzyme, approved 2003) is among the longest-running ultra-high-cost Part B biologics in rare disease, with an annual WAC of roughly $250,000-350,000 and no US biosimilar in twenty-plus years to discipline that price. Its administration route is the first pricing-strategy fork: Fabrazyme and pegunigalsidase alfa (Elfabrio) route to the Medicare Part B medical benefit as infused therapies, while migalastat (Galafold), an oral chaperone reimbursed only for the roughly 35-50% of patients with an amenable GLA mutation, routes to Part D. That routing split changes who bears out-of-pocket cost and which formulary process a manufacturer negotiates through, well before any rebate conversation begins.
The second fork is the IRA orphan-drug exclusion itself. Because Fabrazyme's only FDA-approved indication is Fabry disease, it is excluded from Medicare Drug Price Negotiation under the IRA's orphan-drug provision, a structural shield unrelated to its price level or its market tenure. No disclosed rebate, net-price, or gross-to-net figure exists for Fabrazyme, Elfabrio, or Galafold anywhere in the CMS Part B Drug Spending Dashboard, FDA regulatory record, or major payer coverage policy we reviewed. That is not a research gap to be closed with an estimate; it is the defining commercial fact of this market. A Fabry pricing strategy is built around the orphan-exclusion shield and the Part B versus Part D routing decision, not around a rebate waterfall that does not exist in the public record for this disease.
US Fabry therapies are priced under an orphan-exclusion shield, not a disclosed rebate table
| Agent | Medicare Routing | Annual WAC | IRA Negotiation Status |
|---|---|---|---|
| Fabrazyme (agalsidase beta) | Part B (medical benefit) | $250,000-350,000 | Excluded, sole orphan Fabry indication; no US biosimilar |
| Elfabrio (pegunigalsidase alfa) | Part B (medical benefit) | Not disclosed | Sole orphan Fabry indication |
| Galafold (migalastat) | Part D (pharmacy benefit) | Not disclosed | Amenable-mutation gate via HEK293 assay; sole orphan Fabry indication |
Sources: CMS IRA Drug Price Negotiation framework and Part B Drug Spending Dashboard; FDA Drugs@FDA; NICE Highly Specialised Technology guidance HST4 (2017); G-BA/IQWiG 2016 migalastat early benefit assessment (AMNOG); major payer coverage policies.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The IRA's orphan-drug exclusion mechanism and why a single approved indication triggers it
- the pricing-strategy implication of a negotiation-shielded ultra-high-cost biologic
Delivers
- Fabrazyme and Elfabrio's Part B medical-benefit routing versus migalastat's Part D pharmacy-benefit routing
- the out-of-pocket and formulary-negotiation consequences of each
Delivers
- Confirmation that no rebate, net-price, or GTN figure is disclosed for Fabrazyme, Elfabrio, or Galafold in the primary record
- the pricing-model structure built around WAC and orphan-exclusion status instead
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the IRA orphan-drug exclusion, not a rebate ladder, defines Fabry pricing strategy in the US
- Pressure-tested against the absence of any disclosed net-price figure for Fabrazyme, Elfabrio, or Galafold
- Fabrazyme's $250,000-350,000/year WAC and its two-decade tenure without a US biosimilar
- Elfabrio and Galafold pricing context
- How the single-indication exclusion applies to Fabrazyme
- What this shield means for long-run price trajectory
- Fabrazyme and Elfabrio's Part B medical-benefit routing
- Migalastat's Part D pharmacy-benefit routing and the amenable-mutation gate
- Why no rebate or GTN figure is disclosed for any approved Fabry therapy
- What this absence means for pricing-strategy assumptions
- European HTA precedent for migalastat referenced informally by US payers
- Where ex-US precedent does and does not transfer to a negotiation-shielded US market
- Sequencing recommendation for a new Fabry entrant
- Conservative, base, and aggressive revenue scenarios
- The open pricing questions your team must close before a US Fabry launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory and payer-policy sources. Where no rebate or net-price figure is disclosed anywhere in the primary record, the model states that gap explicitly rather than substituting an estimate.
Fabry disease US pricing sources: CMS IRA Drug Price Negotiation framework and Part B Drug Spending Dashboard; FDA Drugs@FDA; NICE Highly Specialised Technology guidance HST4 (2017); G-BA/IQWiG 2016 migalastat early benefit assessment (AMNOG); and current major payer coverage policies.
- Fabrazyme's IRA orphan-drug exclusion verified against the CMS IRA Drug Price Negotiation framework
- Fabrazyme WAC and no-US-biosimilar status verified against FDA Drugs@FDA and the CMS Part B Drug Spending Dashboard
- Part B versus Part D routing verified against CMS drug classification and benefit design documentation
- Absence of a disclosed rebate or net-price figure for Fabrazyme, Elfabrio, and Galafold confirmed across the full primary regulatory and payer-policy record reviewed; no estimate was substituted
Frequently asked questions
Commission this model
AXLRx delivers Fabry disease pricing strategy models built for market access and pricing teams navigating an orphan-exclusion-shielded US biologic class. Custom model in 72 hours.
Specify your indication, target payer segment, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions before building.
Research-verified pricing model in 72 hours with optional analyst readout.